

# Ute I Schwarz

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/7932318/ute-i-schwarz-publications-by-year.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

42  
papers

3,705  
citations

22  
h-index

44  
g-index

44  
ext. papers

4,023  
ext. citations

6  
avg, IF

4.55  
L-index

#	Paper	IF	Citations
42	Association of Sex With Stroke and Bleeding Risk of Apixaban and Rivaroxaban in Elderly Atrial Fibrillation Patients Using Propensity Score Weights.. <i>CJC Open</i> , <b>2022</b> , 4, 56-64	2	0
41	Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events. <i>Clinical and Translational Science</i> , <b>2021</b> , 14, 1338-1348	4.9	3
40	Organic Anion Transporting Polypeptide 2B1 (OATP2B1) Genetic Variants: Functional Characterization and Association With Circulating Concentrations of Endogenous Substrates. <i>Frontiers in Pharmacology</i> , <b>2021</b> , 12, 713567	5.6	0
39	Novel variant in glycoprotein c gene protects against ribavirin-induced anemia during chronic hepatitis C treatment. <i>Biomedicine and Pharmacotherapy</i> , <b>2021</b> , 143, 112195	7.5	0
38	Variant discovery using next-generation sequencing and its future role in pharmacogenetics. <i>Pharmacogenomics</i> , <b>2020</b> , 21, 471-486	2.6	4
37	Drug interactions and pharmacogenetic factors contribute to variation in apixaban concentration in atrial fibrillation patients in routine care. <i>Journal of Thrombosis and Thrombolysis</i> , <b>2020</b> , 49, 294-303	5.1	14
36	Fexofenadine and Rosuvastatin Pharmacokinetics in Mice with Targeted Disruption of Organic Anion Transporting Polypeptide 2B1. <i>Drug Metabolism and Disposition</i> , <b>2019</b> , 47, 832-842	4	22
35	Targeted next generation sequencing as a tool for precision medicine. <i>BMC Medical Genomics</i> , <b>2019</b> , 12, 81	3.7	26
34	Apixaban Concentrations with Lower than Recommended Dosing in Older Adults with Atrial Fibrillation. <i>Journal of the American Geriatrics Society</i> , <b>2019</b> , 67, 1902-1906	5.6	9
33	Differences in Warfarin Pharmacodynamics and Predictors of Response Among Three Racial Populations. <i>Clinical Pharmacokinetics</i> , <b>2019</b> , 58, 1077-1089	6.2	9
32	The Role of Next-Generation Sequencing in Pharmacogenetics and Pharmacogenomics. <i>Cold Spring Harbor Perspectives in Medicine</i> , <b>2019</b> , 9,	5.4	31
31	Apixaban and Rosuvastatin Pharmacokinetics in Nonalcoholic Fatty Liver Disease. <i>Drug Metabolism and Disposition</i> , <b>2018</b> , 46, 485-492	4	12
30	Polymorphism Predisposes to Dopamine Overdose in Parkinson's Disease. <i>Frontiers in Neurology</i> , <b>2018</b> , 9, 693	4.1	12
29	Characterization of OATP1B3 and OATP2B1 transporter expression in the islet of the adult human pancreas. <i>Histochemistry and Cell Biology</i> , <b>2017</b> , 148, 345-357	2.4	7
28	Interpatient Variation in Rivaroxaban and Apixaban Plasma Concentrations in Routine Care. <i>Canadian Journal of Cardiology</i> , <b>2017</b> , 33, 1036-1043	3.8	38
27	Ontogeny of human hepatic and intestinal transporter gene expression during childhood: age matters. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 1268-74	4	101
26	OATP1B3 is expressed in pancreatic islet cells and enhances the insulinotropic effect of the sulfonylurea derivative glibenclamide. <i>Diabetes</i> , <b>2014</b> , 63, 775-84	0.9	22

25	Incremental lowering of low-density lipoprotein cholesterol with ezetimibe 20 mg vs 10 mg daily in patients receiving concomitant statin therapy. <i>Canadian Journal of Cardiology</i> , <b>2013</b> , 29, 1395-9	3.8	3
24	Clinical and pharmacogenetic predictors of circulating atorvastatin and rosuvastatin concentrations in routine clinical care. <i>Circulation: Cardiovascular Genetics</i> , <b>2013</b> , 6, 400-8		124
23	Genetic and clinical determinants of CYP3A4 activity in patients using 4βhydroxycholesterol as an in vivo probe. <i>FASEB Journal</i> , <b>2013</b> , 27, 672.3	0.9	
22	Clarifying the importance of CYP2C19 and PON1 in the mechanism of clopidogrel bioactivation and in vivo antiplatelet response. <i>European Heart Journal</i> , <b>2012</b> , 33, 2856-2464a	9.5	58
21	Cytochrome P450 2D6 phenotyping in an elderly population with dementia and response to galantamine in dementia: a pilot study. <i>American Journal of Geriatric Pharmacotherapy</i> , <b>2011</b> , 9, 224-33		14
20	Hepatic organic anion transporting polypeptide transporter and thyroid hormone receptor interplay determines cholesterol and glucose homeostasis. <i>Hepatology</i> , <b>2011</b> , 54, 644-54	11.2	20
19	Identification of novel functional organic anion-transporting polypeptide 1B3 polymorphisms and assessment of substrate specificity. <i>Pharmacogenetics and Genomics</i> , <b>2011</b> , 21, 103-14	1.9	66
18	Clinical and genetic determinants of warfarin pharmacokinetics and pharmacodynamics during treatment initiation. <i>PLoS ONE</i> , <b>2011</b> , 6, e27808	3.7	52
17	Fatal hydrocodone overdose in a child: pharmacogenetics and drug interactions. <i>Pediatrics</i> , <b>2010</b> , 126, e986-9	7.4	75
16	Human skeletal muscle drug transporters determine local exposure and toxicity of statins. <i>Circulation Research</i> , <b>2010</b> , 106, 297-306	15.7	149
15	Relative contribution of CYP2C9 and VKORC1 genotypes and early INR response to the prediction of warfarin sensitivity during initiation of therapy. <i>Blood</i> , <b>2009</b> , 113, 3925-30	2.2	74
14	Genetic determinants of response to warfarin during initial anticoagulation. <i>New England Journal of Medicine</i> , <b>2008</b> , 358, 999-1008	59.2	436
13	Breast cancer resistance protein (ABCG2) and drug disposition: intestinal expression, polymorphisms and sulfasalazine as an in vivo probe. <i>Pharmacogenetics and Genomics</i> , <b>2008</b> , 18, 439-48	1.9	109
12	Induction of intestinal P-glycoprotein by St John's wort reduces the oral bioavailability of talinolol. <i>Clinical Pharmacology and Therapeutics</i> , <b>2007</b> , 81, 669-78	6.1	118
11	Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. <i>British Journal of Clinical Pharmacology</i> , <b>2006</b> , 62, 485-91	3.8	20
10	Genetic determinants of dose and clinical outcomes in patients receiving oral anticoagulants. <i>Clinical Pharmacology and Therapeutics</i> , <b>2006</b> , 80, 7-12	6.1	21
9	Grapefruit juice ingestion significantly reduces talinolol bioavailability. <i>Clinical Pharmacology and Therapeutics</i> , <b>2005</b> , 77, 291-301	6.1	112
8	Coordinate induction of both cytochrome P4503A and MDR1 by St John's wort in healthy subjects. <i>Clinical Pharmacology and Therapeutics</i> , <b>2003</b> , 73, 41-50	6.1	184

7	Unwanted pregnancy on self-medication with St John's wort despite hormonal contraception. <i>British Journal of Clinical Pharmacology</i> , <b>2003</b> , 55, 112-3	3.8	81
6	Fruit juices inhibit organic anion transporting polypeptide-mediated drug uptake to decrease the oral availability of fexofenadine. <i>Clinical Pharmacology and Therapeutics</i> , <b>2002</b> , 71, 11-20	6.1	453
5	MDR1 gene polymorphisms affect therapy outcome in acute myeloid leukemia patients. <i>Cancer Research</i> , <b>2002</b> , 62, 4955-62	10.1	153
4	Identification of functionally variant MDR1 alleles among European Americans and African Americans. <i>Clinical Pharmacology and Therapeutics</i> , <b>2001</b> , 70, 189-99	6.1	773
3	Identification and functional characterization of a new CYP2C9 variant (CYP2C9*5) expressed among African Americans. <i>Molecular Pharmacology</i> , <b>2001</b> , 60, 382-7	4.3	248
2	Unexpected effect of verapamil on oral bioavailability of the beta-blocker talinolol in humans. <i>Clinical Pharmacology and Therapeutics</i> , <b>1999</b> , 65, 283-90	6.1	42
1	Outpatient costs of osteoporosis in a national health insurance population. <i>Clinical Therapeutics</i> , <b>1999</b> , 21, 2001-14	3.5	9